Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of S-777469. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 known ✓ | P34972 | 20/20 | 1.00 |
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523027 | 0.92 | CNR2 (0.86) | CNR2CNR1 | |
| SCHEMBL5523050 | 0.91 | CNR2 (0.84) | CNR2CNR1 | |
| SCHEMBL5525745 | 0.91 | CNR2 (0.84) | CNR2CNR1 | |
| SCHEMBL5525217 | 0.91 | CNR2 (0.84) | CNR2CNR1 | |
| SCHEMBL5525296 | 0.91 | CNR2 (0.83) | CNR2CNR1FAAH | |
| SCHEMBL2746162 | 0.91 | CNR2 (0.83) | CNR2CNR1FAAHABHD12 | |
| SCHEMBL5519003 | 0.90 | CNR2 (0.82) | CNR2CNR1 | |
| SCHEMBL5524762 | 0.89 | CNR2 (0.81) | CNR2CNR1FAAHABHD12 | |
| SCHEMBL5525266 | 0.89 | CNR2 (0.80) | CNR2CNR1FAAH | |
| SCHEMBL5521578 | 0.89 | CNR2 (0.80) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | ANTERIOS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| CN-119367374-A | Potentilla acid compound as CB2 receptor agonist, medicament and application | 赣江中药创新中心 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024257801-A1 | ADJUVANT AND COMPOSITION THEREOF | デンカ株式会社 | 2024-12-19 | — | — | WO | disclosed |
| US-20240158384-A1 | CB2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-05-16 | — | — | US | disclosed |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | WYLDER NATION FOUNDATION | 2023-06-15 | — | — | US | disclosed |
| EP-4153169-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | Wylder Nation Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220387299-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | ANTERIOS, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022132803-A1 | CB2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | CNR2 1/4885CNR1 2/4885FAAH 113/4885 |
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | TSG101, NPC1L1, NPC1 | CNR2 3674/4885CNR1 2736/4885FAAH 3768/4885 |
| US-20240158384-A1 | CB2 RECEPTOR AGONISTS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885FAAH 87/4885 |
| US-20220387299-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | TSG101, NPC1L1, NPC1 | CNR2 3674/4885CNR1 2736/4885FAAH 3768/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885FAAH 146/4885 |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | GBA1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885FAAH 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.